Clinical and molecular characteristics of HCL patients before treatment
| Characteristic . | n/total (%) . | Median (range) . |
|---|---|---|
| Age, y | 51 (30-83) | |
| Males | 46/58 (79) | — |
| Females | 12/58 (21) | — |
| ECOG performance status | ||
| 0 | 45/58 (77) | — |
| 1 | 10/58 (17) | — |
| 2 | 2/58 (6) | — |
| Time from diagnosis to treatment, d | 31 (4-376) | |
| Follow-up, mo | 24 (6-40) | |
| Splenomegaly | 32/58 (55) | — |
| Splenomegaly, cm bcm | 2 (0-16) | |
| Bulky spleen (≥ 10 cm bcm) | 8/58 (14) | — |
| Lymph nodes > 1.5 cm | 6/58 (10) | |
| Hemoglobin | 11.4 (5.2-16) | |
| Less than 12 g/dL | 33/58 (57) | — |
| Less than 10 g/dL | 12/58 (21) | — |
| Less than 9 g/dL | 9/58 (16) | — |
| Less than 8 g/dL | 5/58 (9) | — |
| Platelets | 75 (30-237) | |
| Less than 100 × 103/μL | 44/58 (76) | — |
| Less than 50 × 103/μL | 9/58 (16) | — |
| WBCs | 3.1 (0.9-48) | |
| More than 10 × 103/μL | 6/58 (10)* | — |
| Less than 4 × 103/μL | 38/58 (66) | — |
| Neutrophils | 0.9 (0.104-4.8) | |
| Less than 1.5 × 103/μL | 50/58 (86) | — |
| Less than 0.5 × 103/μL | 15/58 (26) | — |
| Percentage of HCs in peripheral blood counts* | 11 (1-93) | |
| Percentage of HCs of all peripheral blood B cells* | 80 (30-99) | |
| B2M > × 1 ULN | 27/46 (59) | — |
| B2M> × 2 ULN | 3/46 (7) | — |
| LDH > × 1 ULN | 4/58 (7) | — |
| Hairy cell index, n = 55 | 0.42 (0.06-0.9) | |
| Molecular characteristics | ||
| IGHV homology ≥ 98% | 6/58 (10) | — |
| TP53 dysfunction† | 2/58 (2) | — |
| Characteristic . | n/total (%) . | Median (range) . |
|---|---|---|
| Age, y | 51 (30-83) | |
| Males | 46/58 (79) | — |
| Females | 12/58 (21) | — |
| ECOG performance status | ||
| 0 | 45/58 (77) | — |
| 1 | 10/58 (17) | — |
| 2 | 2/58 (6) | — |
| Time from diagnosis to treatment, d | 31 (4-376) | |
| Follow-up, mo | 24 (6-40) | |
| Splenomegaly | 32/58 (55) | — |
| Splenomegaly, cm bcm | 2 (0-16) | |
| Bulky spleen (≥ 10 cm bcm) | 8/58 (14) | — |
| Lymph nodes > 1.5 cm | 6/58 (10) | |
| Hemoglobin | 11.4 (5.2-16) | |
| Less than 12 g/dL | 33/58 (57) | — |
| Less than 10 g/dL | 12/58 (21) | — |
| Less than 9 g/dL | 9/58 (16) | — |
| Less than 8 g/dL | 5/58 (9) | — |
| Platelets | 75 (30-237) | |
| Less than 100 × 103/μL | 44/58 (76) | — |
| Less than 50 × 103/μL | 9/58 (16) | — |
| WBCs | 3.1 (0.9-48) | |
| More than 10 × 103/μL | 6/58 (10)* | — |
| Less than 4 × 103/μL | 38/58 (66) | — |
| Neutrophils | 0.9 (0.104-4.8) | |
| Less than 1.5 × 103/μL | 50/58 (86) | — |
| Less than 0.5 × 103/μL | 15/58 (26) | — |
| Percentage of HCs in peripheral blood counts* | 11 (1-93) | |
| Percentage of HCs of all peripheral blood B cells* | 80 (30-99) | |
| B2M > × 1 ULN | 27/46 (59) | — |
| B2M> × 2 ULN | 3/46 (7) | — |
| LDH > × 1 ULN | 4/58 (7) | — |
| Hairy cell index, n = 55 | 0.42 (0.06-0.9) | |
| Molecular characteristics | ||
| IGHV homology ≥ 98% | 6/58 (10) | — |
| TP53 dysfunction† | 2/58 (2) | — |
WBCs indicates white blood cells; HCs, hairy cells; B2M, β2-microglobulin; LDH, lactic dehydrogenase; —, not applicable; and ULN, upper limit of normal.
The percentage of HCs in peripheral blood was determined by morphologic examination of the peripheral blood smear; the percentage of HCs of all peripheral blood B cells was calculated in flow cytometry by double staining of PBMCs with anti-CD20 and anti-CD103 monoclonal antibodies. CD20+ B cells were gated and the percentage of CD20+CD103+ HC cells was determined.
Twelve of 60 cases were investigated for the whole genome DNA profile by using the 250K Affymetrix array: these included 3 of 5 NR + mR and 9 of 53 PR + CR. Of the 5 NR + mR HCLs, 2 had TP53 dysfunction by p53 mutation.